Vortioxetine (Brintellix®) and levomilnacipran (fetzima®): The two newest additions to the antidepressant formulary

Issues in Mental Health Nursing

Volumn 35, Issue 12, 2014, Pages 972-974

  Roman, Marian W ^a   Wilkinson, Shannon M ^a  

^a Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE; MILNACIPRAN; PIPERAZINE DERIVATIVE; SULFIDE; VORTIOXETINE;

DEPRESSIVE DISORDER, MAJOR; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; NURSING; PSYCHOLOGY; UNITED STATES;

ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DRUG APPROVAL; HUMANS; PIPERAZINES; SULFIDES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84913584664     PISSN: 01612840     EISSN: 10964673     Source Type: Journal    
DOI: 10.3109/01612840.2014.955155     Document Type: Article

References (15)

1. Alavarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012). A double-blind, randomized, placebo-controlled, active reference study of LuAA21004 in patient with major depressive disorder. International Journal of Neuropsy-chopharmacology, 15, 589-600. doi: 10.1017/S1461145711001027
2. Auclair, A. L., Martel, J. C., Assié, M. B., Bardin, L., Heusler, P., Cussac, D.,.. Depoortère, R. (2013). Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety. Neuropharmacology, 70, 338-347.
3. Bang-Anderson, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G.,.. Stensbøl, T. B. (2011). Discovery of 1-[2-(2, 4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A novel multi-modal compound for the treatment of major depressive disorder. Journal of Medicinal Chemistry, 54, 3206-3221.
4. Boulenger, J., Loft, H., & Florea, I. (2012). A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. Journal of Psychopharmacology, 26(11), 1408-1416. doi:10.1177/0269881112441866
5. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189-198.
6. Forest Laboratories, Inc. (2014). Fetzima. Retrieved from http://medlibrary. org/lib/rx/meds/fetzima/
7. Glennon, R. A., Dukat, M., & Westkaemper, R. B. (2002). Serotonin receptor subtypes and ligands.. In: Davis, K. L., Charney, D., Coyle, J. T., Nemeroff, C. (Eds). Philadelphia: Lippincott Williams & Wilkins.
8. Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56-62. doi: 10.1136/jnnp.23.1.56 PMID 14399272
9. Malenka, R. (2010). Intercellular communication in the nervous system. Waltham, MA: Academic.
10. Montgomery, S. A., & Asberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134(4), 382-389. doi: 10.1192/bjp.134.4.382 PMID 444788
11. National Alliance on Mental Illness. (2013a). Vortioxetine. Retrieved from http://www.nami.org/Template.cfm?Section=Helpline1&Template=/Content Management/ContentDisplay.cfm&ContentID=164493
12. National Alliance on Mental Illness. (2013b). Levomilnacipran. Retrieved from http://www.nami.org/Template.cfm?Section=Helpline1&Template=/Content Management/ContentDisplay.cfm&ContentID=164486
13. Saraceni, M. M., Venci, J. V., & Gandhi, M. A. (2013, December 31). Levom-ilnacipran (Fetzima): A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder. Journal of Pharmacy Practice. doi: 10.1177/0897190013516504
14. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). New York, NY: Cambridge University Press.
15. Takeda Pharmaceuticals. (2013, September). Brintellix package insert. Con-shohocken, PA: Author.